Silo Pharma and Kymanox Join Forces for SP-26 Ketamine Implant Device Targeting Pain Management
Shots:
- Silo Pharma has collaborated with Kymanox (SC insertaion device) to develop for SP-26 targeting fibromyalgia and chronic pain. Kymanox also serves as Silo’s regulatory partner for SPC-15, a prophylactic treatment for stress-induced disorders like PTSD
- Kymanox will lead SP-26's proof-of-concept design, prototype development, and feasibility testing to find optimal tissue insertion depth. Its preclinical study focused on SP-26 meeting FDA safety standards for potential at-home use
- Silo’s SP-26 is a ketamine-based dissolvable implant for chronic pain and fibromyalgia, designed for controlled dosage and time release
Ref: Silo Pharma | Image: Silo Pharma & Kymanox
Related News:- Silo Pharma with Sever Pharma Solutions Obtains Regulatory Approval to Conduct the Development of Ketamine Implant for Fibromyalgia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
